Recombinant Human Thrombopoietin
- Generic Name
- Recombinant Human Thrombopoietin
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- E2E529W34D
- Background
Recombinant human thrombopoietin is a full-length glycosylated cytokine produced by Chinese hamster ovary cells and is used to promote the generation of megakaryocytes and platelets. This drug is used in the treatment of thrombocytopenia.
- Indication
用于治疗实体肿瘤化疗后所致的血小板减少症，使用对象为血小板低于50×109/L且医生认为有必要升高血小板数目。
- Associated Conditions
- -
- Associated Therapies
- -
Trial of Primary Prophylaxis With rhTPO Administered to Patients With High Risk Sarcoma Receiving Intensive Chemotherapy
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-01-30
- Last Posted Date
- 2018-10-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT00283582
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy
Phase 1
Completed
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT00187109
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath